Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that it has closed of its previously announced registered direct offering. The offering comprised 3,414,970 shares of POAI’s common stock, offered at a purchase price of $1.20 per share, which was priced at-the-market under Nasdaq rules. … Continue reading “NetworkNewsBreaks – Predictive Oncology (NASDAQ: POAI) Closes Registered Direct Offering for $4.1 Million”
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that it has closed on its previously announced registered direct offering; the company also announced that it has completed definitive agreements with a number of institutional and accredited investors for a registered direct offering. According … Continue reading “NetworkNewsBreaks – Predictive Oncology (NASDAQ: POAI) Closes Registered Direct Offering for $2.2 Million, Announces $4.1 Million Registered Direct Offering”
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has entered into definitive agreements for the issuance and sale of more than 2 million shares of its common stock. The company announced that it has finalized definitive agreements with a number of institutional and accredited … Continue reading “NetworkNewsBreaks – Predictive Oncology (NASDAQ: POAI) Announced Definitive Agreements for $2.2 Million Registered Direct Offering”
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has announced that TumorGenesis, POAI’s wholly owned subsidiary, sold media to top research medical centers in New York City and Boston. The announcement noted that those two sales are repeat orders and focus on culturing ovarian … Continue reading “NetworkNewsBreaks – Predictive Oncology (NASDAQ: POAI) Subsidiary Sells Media to Top Research Medical Centers”
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced the closing of its previously disclosed registered direct offering of 3,650,840 shares of its common stock, at a purchase price of $0.842 per share, priced at-the-market under Nasdaq rules. Predictive Oncology secured $3.074 million … Continue reading “NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Secures $3.074M in Registered Direct Offering”
Predictive Oncology (NASDAQ: POAI) is a knowledge-driven precision medicine company focused on applying data and artificial intelligence (“AI”) to personalized medicine and drug discovery. The company is building a business around an emerging approach to disease prevention and treatment that identifies the variability in genes, environment and lifestyle for each individual, and then uses that … Continue reading “NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Focuses on Multi-Omic Approach to Personalized Treatment Options”
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that it has entered into definitive agreements with several institutional and accredited investors for the issuance and sale of an aggregate of 3,650,840 shares of its common stock at a purchase price of $0.842 … Continue reading “NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces $3M Registered Direct Offering”
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that its wholly owned subsidiary Helomics has completed the integration of Quantitative Medicine’s (“QM”) novel active-learning Computational Research Engine (CoRE(TM)). According to the update, CoRE was integrated with Helomics’ proprietary TumorSpace(TM) knowledgebase of 150,000 … Continue reading “NetworkNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Helomics Completes QM CoRE(TM) Integration”
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has announced that it has hired an investor relations firm. POAI has chosen Landon Capital to provide investor relations services; the agreement was effective Dec. 30, 2020. The announcement noted that anticipated services would include introductions to … Continue reading “NetworkNewsBreaks – Predictive Oncology (NASDAQ: POAI) Engages Investor Relations Firm”
Predictive Oncology’s (NASDAQ: POAI) Board of Directors has announced that it will cancel the Special Meeting of Stockholders that was scheduled for today. Originally scheduled for Dec. 1, 2020, the meeting was adjourned on that date and rescheduled for Dec. 30 because a quorum had not been reached. As of the rescheduled date, the required … Continue reading “NetworkNewsBreaks – Predictive Oncology (NASDAQ: POAI) Cancels Upcoming Special Meeting of Stockholders”
